5 research outputs found
Metabolic clustering analysis as a strategy for compound selection in the drug discovery pipeline for leishmaniasis
A lack of viable hits, increasing resistance, and limited knowledge on mode of action is hindering drug discovery for many diseases. To optimize prioritization and accelerate the discovery process, a strategy to cluster compounds based on more than chemical structure is required. We show the power of metabolomics in comparing effects on metabolism of 28 different candidate treatments for Leishmaniasis (25 from the GSK Leishmania box, two analogues of Leishmania box series, and amphotericin B as a gold standard treatment), tested in the axenic amastigote form of Leishmania donovani. Capillary electrophoresis–mass spectrometry was applied to identify the metabolic profile of Leishmania donovani, and principal components analysis was used to cluster compounds on potential mode of action, offering a medium throughput screening approach in drug selection/prioritization. The comprehensive and sensitive nature of the data has also made detailed effects of each compound obtainable, providing a resource to assist in further mechanistic studies and prioritization of these compounds for the development of new antileishmanial drugs
Essential bromodomain TcBDF2 as a drug target against Chagas disease
Trypanosoma cruzi is a unicellular parasite that causes Chagas disease, which is endemic in the American continent but also worldwide, distributed by migratory movements. A striking feature of trypanosomatids is the polycistronic transcription associated with post-transcriptional mechanisms that regulate the levels of translatable mRNA. In this context, epigenetic regulatory mechanisms have been revealed to be of great importance, since they are the only ones that would control the access of RNA polymerases to chromatin. Bromodomains are epigenetic protein readers that recognize and specifically bind to acetylated lysine residues, mostly at histone proteins. There are seven coding sequences for BD-containing proteins in trypanosomatids, named TcBDF1 to TcBDF7, and a putative new protein containing a bromodomain was recently described. Using the Tet-regulated overexpression plasmid pTcINDEX-GW and CRISPR/Cas9 genome editing, we were able to demonstrate the essentiality of TcBDF2 in T. cruzi. This bromodomain is located in the nucleus, through a bipartite nuclear localization signal. TcBDF2 was shown to be important for host cell invasion, amastigote replication, and differentiation from amastigotes to trypomastigotes. Overexpression of TcBDF2 diminished epimastigote replication. Also, some processes involved in pathogenesis were altered in these parasites, such as infection of mammalian cells, replication of amastigotes, and the number of trypomastigotes released from host cells. In in vitro studies, TcBDF2 was also able to bind inhibitors showing a specificity profile different from that of the previously characterized TcBDF3. These results point to TcBDF2 as a druggable target against T. cruzi
Metabolic Clustering Analysis as a Strategy for Compound Selection in the Drug Discovery Pipeline for Leishmaniasis
A lack
of viable hits, increasing resistance, and limited knowledge
on mode of action is hindering drug discovery for many diseases. To
optimize prioritization and accelerate the discovery process, a strategy
to cluster compounds based on more than chemical structure is required.
We show the power of metabolomics in comparing effects on metabolism
of 28 different candidate treatments for Leishmaniasis (25 from the
GSK Leishmania box, two analogues of Leishmania box series, and amphotericin
B as a gold standard treatment), tested in the axenic amastigote form
of <i>Leishmania donovani</i>. Capillary electrophoresis–mass
spectrometry was applied to identify the metabolic profile of <i>Leishmania donovani</i>, and principal components analysis was
used to cluster compounds on potential mode of action, offering a
medium throughput screening approach in drug selection/prioritization.
The comprehensive and sensitive nature of the data has also made detailed
effects of each compound obtainable, providing a resource to assist
in further mechanistic studies and prioritization of these compounds
for the development of new antileishmanial drugs
Metabolic Clustering Analysis as a Strategy for Compound Selection in the Drug Discovery Pipeline for Leishmaniasis
A lack
of viable hits, increasing resistance, and limited knowledge
on mode of action is hindering drug discovery for many diseases. To
optimize prioritization and accelerate the discovery process, a strategy
to cluster compounds based on more than chemical structure is required.
We show the power of metabolomics in comparing effects on metabolism
of 28 different candidate treatments for Leishmaniasis (25 from the
GSK Leishmania box, two analogues of Leishmania box series, and amphotericin
B as a gold standard treatment), tested in the axenic amastigote form
of <i>Leishmania donovani</i>. Capillary electrophoresis–mass
spectrometry was applied to identify the metabolic profile of <i>Leishmania donovani</i>, and principal components analysis was
used to cluster compounds on potential mode of action, offering a
medium throughput screening approach in drug selection/prioritization.
The comprehensive and sensitive nature of the data has also made detailed
effects of each compound obtainable, providing a resource to assist
in further mechanistic studies and prioritization of these compounds
for the development of new antileishmanial drugs
A Focused Screen Identifies Antifolates with Activity on Mycobacterium tuberculosis
Antifolates are widely used to treat
several diseases but are not
currently used in the first-line treatment of tuberculosis, despite
evidence that some of these molecules can target Mycobacterium
tuberculosis (Mtb) bacilli in vitro. To identify new
antifolate candidates for animal-model efficacy studies of tuberculosis,
we paired knowledge and tools developed in academia with the infrastructure
and chemistry resources of a large pharmaceutical company. Together
we curated a focused library of 2508 potential antifolates, which
were then tested for activity against live Mtb. We identified 210
primary hits, confirmed the on-target activity of potent compounds,
and now report the identification and characterization of 5 hit compounds,
representative of 5 different chemical scaffolds. These antifolates
have potent activity against Mtb and represent good starting points
for improvement that could lead to in vivo efficacy studies